Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes

References

• Linsenmeier RA, Goldstick TK, Blum RS, Enroth-Cugell C. Estimation of retinal oxygen transients from measurements made in the vitreous humor. Exp Eye Res 1981;32:369–79.
   PubMed Web of Science ®Google Scholar
• Ko F, Foster PJ, Strouthidis NG, Shweich Y, Yang Q, Reisman CA, Muthy ZA, Chakravarthy U, Lotery AJ, Keane PA, et al. Associations with retinal pigment epithelium measures in a large cohort: results from the UK biobank. Ophthalmology 2017;124:105–17.
   PubMed Web of Science ®Google Scholar
• Abdolrahimzadeh S, Parisi F, Scavella V, Recupero SM. Optical coherence tomography evidence on the correlation of choroidal thickness and age with vascularized retinal layers in normal eyes. Retina 2016;36:2329–38.
   PubMed Web of Science ®Google Scholar
• Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S. Subfoveal choroidal thickness in typical age-related macular degenerarion and polypoid choroidal vasculopthay. Graefes Arch Clin Exp Ophthalmol 2011;249:1123–28.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim JR, Kang SW, Kim SJ, Ha SH. Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. Am J Ophtalmol 2013;155(743–9):e1–2.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Koizumi H, Yamagishi Y, Kinoshita S. Subfoveal choroidal thickness in retinal angiomatous proliferation. Retina 2014;34:1316–22.
   PubMed Web of Science ®Google Scholar
• Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC. Sufoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical age-related macular degeneration. Am J Ophthalmol 2014;157:1013–21.
   PubMed Web of Science ®Google Scholar
• Julien S, Biesemeier A, Taubitz T, Schraemeyer U. Different aspects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 2014;98:813–25.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee TG, Chang YS, Jim CG, Cho SW. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study. Br J Ophthalmol 2016;100:1634–39.
   Google Scholar
• Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V. Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol The 2015;31:357–62.
   Google Scholar
• Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of aflibercept for treatment-resistant neovascular age related macular degeneration. Biomed Res Int 2014;273754.
   PubMed Web of Science ®Google Scholar
• Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010;30:1333–49.
   PubMed Web of Science ®Google Scholar
• Hata M, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ooto S, Tamura H, Nakanishi H, Takahashi A, Yoshikawa M, et al. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci 2014;55:7874–80.
   PubMed Web of Science ®Google Scholar
• Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim, S, Huh K. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2016;254:1693–702.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fey D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA. Pharmakokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260–66.
   PubMed Web of Science ®Google Scholar
• Simader C, Ritter M, Boltz M, Deàk GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM. Morphological parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014;121:1237–45.
   PubMed Web of Science ®Google Scholar
• Kiss CG, Geitzenauer W, Simader C, Gregori C, Schmidt-Erfurth U. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomography retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376–83.
   PubMed Web of Science ®Google Scholar
• Martin DF, MacGuire MG, Fine SL, Ying GS, Jaffe GL, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–98.
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5mg or 2.0mg of ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046–56.
   Google Scholar
• Schmidt-Erfurth U, Chong V, Loewnstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F, Guidelines for the management of neovascular age-related macular degeneration by the European society of retinal specialists (EURETINA). Br J Ophthalmol 2014;98:1144–67.
   PubMed Web of Science ®Google Scholar
• Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222–26.
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667–68.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171–85.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci 2002;99:11393–98.
   PubMed Web of Science ®Google Scholar
• Gharbiya M, Parisi F, Cruciani F, Bozzoni-Pantaleoni F, Pranno F, Abdolrahimzadeh S. Intravitreal antivascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long term functional and anatomical results using a modified PrONTO-style regimen. Retina 2014;34:298–305.
   PubMed Web of Science ®Google Scholar
• McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina 2011;31:1043–52.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, Ying G, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-realated macular degeneraton treatment trials. Ophthalmology 2014;121:150–61.
   PubMed Web of Science ®Google Scholar